editorials · reviews · multicenter studies · meta-analyses · randomized controlled trials · retractions
Cancer discovery · Sep 2015
The BTK inhibitor ibrutinib is preferentially effective in patients with the ABC subtype of DLBCL.
read more… mark as read…
expand abstract… mark as read…
We guarantee your privacy. Your email address will not be shared.
Receive a weekly email with the highest quality and most significant abstracts from critical care specialties.
Anesthesiology, Critical Care Medicine, Emergency Medicine, Medicine, and Pain medicine.
Includes a free 21 day trial of metajournal premium
We guarantee your privacy. Your email address will not be shared. Unsubscribe anytime.